


Amendments to the Claims

This claim listing replaces all prior versions and listings of claims in the application.

1-13. (Cancelled).

14. (Currently amended) A method of accelerating the start of growth of quiescent follicles in non-menopausal women comprising administering to a patient in need thereof a medicament comprising a somatostatin antagonist analog having the general formula (III)



in which:

A^1 is an optionally substituted aromatic α -amino acid;

A^2 is an optionally substituted aromatic α -amino acid;

A^3 is Dab, Dap, Lys, or Orn;

A^4 is β -Hydroxyvaline, Ser, Hser, or Thr;

A^5 is an optionally substituted aromatic D- or L- α -amino acid; and

Y^1 is OH, NH_2 or NHR^1 , R^1 is (C_{1-6}) alkyl;

each aromatic α -amino acid being optionally substituted with one or more substituents

independently selected from a halogen atom, NO_2 , OH, CN, (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{2-6})

alkynyl, (C_{1-6}) alkoxy, Bzl, O-Bzl or NR^9R^{10} , wherein R^9 and R^{10} are each independently H,

O, or (C_{1-6}) alkyl; and

each nitrogen atom of a peptide amide bond and the amino group of A^1 are optionally

substituted with a methyl group, with the proviso that there is at least one said methyl group

in a peptide of general formula (III);

~~the or a~~ pharmaceutically acceptable ~~salts salt~~ or protected ~~forms form~~ of said peptides, or ~~a~~
~~combinations combination~~ thereof.


15. (Cancelled).

16-18. (Cancelled).

19. (Previously presented) The method of claim 14, wherein A¹ is Cpa, A² is Pal, A³ is Lys, A⁴ is Thr, and A⁵ is Nal.

20. (Currently amended) The method of claim 19, wherein the somatostatin antagonist analog is Cpa-cyclo(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-2-Nal-NH₂.

21. (Currently amended) The method of claim 14, wherein the somatostatin antagonist analogue analog is:



22. (Currently amended) A method of accelerating the start of growth of quiescent follicles in non-menopausal women comprising administering to a patient in need thereof a medicament


comprising a somatostatin antagonist analog ~~comprising~~ selected from the group consisting of:

the following peptides:

- Cpa-cyclo[D-Cys- Pal-D- Trp-N-Me-Lys- Thr-Cys]-D-Trp-NH₂;
- Cpa-cyclo[D-Cys- Tyr-D-Trp- N-Me-Lys-Thr-Cys]-Nal-NH₂;
- Cpa-cyclo[D-Cys-Pal-D- Trp- N-Me-Lys-Thr-Cys]- Nal-NH₂;



~~the peptide~~ acetyl-D-His-D-Phe-D-Ile-D-Arg-D-Trp-D-Phe-NH₂ (code name AG-178,335);

~~the octapeptide of the following structure~~ (code name ODN-8);





~~the peptide~~ Cpa-cyclo[D-Cys-Pal-D-Trp-Lys-Val-Cys]Cpa-amide (code name SB-710411);



~~the peptide of the following structure~~ (code name BIM-23056);

**BIM 23056**

the compound of the following structure (code name **BN-81674**);

**BN-81674**

the compound of the following structure (code name **SRA-880**); and

**SRA-880**

or their a pharmaceutically acceptable salts salt or protected formsform, or a
combinationcombinations thereof.